Enliven Therapeutics Stock Price Prediction
ELVN Stock | 27.53 2.02 7.92% |
Oversold Vs Overbought
56
Oversold | Overbought |
EPS Estimate Next Quarter (0.60) | EPS Estimate Current Year (1.94) | EPS Estimate Next Year (2.47) | Wall Street Target Price 35.6 | EPS Estimate Current Quarter (0.55) |
Using Enliven Therapeutics hype-based prediction, you can estimate the value of Enliven Therapeutics from the perspective of Enliven Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Enliven Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Enliven because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Enliven Therapeutics after-hype prediction price | USD 27.37 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Enliven |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enliven Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Enliven Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Enliven Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Enliven Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Enliven Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
Expected price to next headline |
Enliven Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Enliven Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Enliven Therapeutics' historical news coverage. Enliven Therapeutics' after-hype downside and upside margins for the prediction period are 23.89 and 30.85, respectively. We have considered Enliven Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Enliven Therapeutics is not too volatile at this time. Analysis and calculation of next after-hype price of Enliven Therapeutics is based on 3 months time horizon.
Enliven Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Enliven Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enliven Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Enliven Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.37 | 3.48 | 0.10 | 0.07 | 10 Events / Month | 7 Events / Month | In about 10 days |
Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
27.53 | 27.37 | 0.58 |
|
Enliven Therapeutics Hype Timeline
Enliven Therapeutics is currently traded for 27.53. The entity has historical hype elasticity of -0.1, and average elasticity to hype of competition of -0.07. Enliven is anticipated to decline in value after the next headline, with the price expected to drop to 27.37. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.58%, whereas the daily expected return is currently at 0.37%. The volatility of related hype on Enliven Therapeutics is about 1870.97%, with the expected price after the next announcement by competition of 27.46. About 93.0% of the company shares are held by institutions such as insurance companies. The book value of Enliven Therapeutics was currently reported as 6.46. The company recorded a loss per share of 1.91. Enliven Therapeutics had not issued any dividends in recent years. The entity had 1:4 split on the 24th of February 2023. Given the investment horizon of 90 days the next anticipated press release will be in about 10 days. Check out Enliven Therapeutics Basic Forecasting Models to cross-verify your projections.Enliven Therapeutics Related Hype Analysis
Having access to credible news sources related to Enliven Therapeutics' direct competition is more important than ever and may enhance your ability to predict Enliven Therapeutics' future price movements. Getting to know how Enliven Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Enliven Therapeutics may potentially react to the hype associated with one of its peers.
HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
PETQ | PetIQ Inc | 0.10 | 11 per month | 0.00 | 0.08 | 1.67 | (2.01) | 48.08 | |
EBS | Emergent Biosolutions | 0.31 | 11 per month | 10.67 | 0.08 | 14.40 | (16.84) | 67.18 | |
BHC | Bausch Health Companies | (0.08) | 10 per month | 4.85 | 0.05 | 3.80 | (3.15) | 26.39 | |
NBIX | Neurocrine Biosciences | (2.09) | 11 per month | 0.00 | (0.13) | 2.32 | (2.66) | 27.05 | |
TEVA | Teva Pharma Industries | (0.31) | 9 per month | 1.70 | (0.02) | 3.21 | (2.65) | 10.54 | |
HLN | Haleon plc | (0.01) | 10 per month | 0.26 | 0.22 | 1.95 | (1.25) | 4.64 | |
TAK | Takeda Pharmaceutical Co | 0.01 | 9 per month | 0.98 | 0.03 | 1.68 | (1.72) | 6.70 | |
ITCI | Intracellular Th | 0.03 | 8 per month | 1.51 | (0.01) | 3.04 | (2.32) | 10.43 | |
CTLT | Catalent | 0.09 | 7 per month | 0.00 | (0.02) | 0.74 | (0.56) | 2.57 | |
AMPH | Amphastar P | 0.09 | 10 per month | 1.65 | 0.08 | 4.07 | (2.79) | 17.12 |
Enliven Therapeutics Additional Predictive Modules
Most predictive techniques to examine Enliven price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Enliven using various technical indicators. When you analyze Enliven charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
About Enliven Therapeutics Predictive Indicators
The successful prediction of Enliven Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Enliven Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Enliven Therapeutics based on analysis of Enliven Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Enliven Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Enliven Therapeutics's related companies. 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 19.24 | 8.0 | 10.28 | 17.11 | Net Debt To EBITDA | 4.46 | 1.95 | 1.22 | 1.16 |
Story Coverage note for Enliven Therapeutics
The number of cover stories for Enliven Therapeutics depends on current market conditions and Enliven Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Enliven Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Enliven Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Enliven Therapeutics Short Properties
Enliven Therapeutics' future price predictability will typically decrease when Enliven Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Enliven Therapeutics often depends not only on the future outlook of the potential Enliven Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enliven Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 35.5 M | |
Cash And Short Term Investments | 253.2 M |
Additional Information and Resources on Investing in Enliven Stock
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:Check out Enliven Therapeutics Basic Forecasting Models to cross-verify your projections. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Return On Assets (0.20) | Return On Equity (0.28) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.